Please Wait...

Post-Approval Research

Powerful Post-Approval Operational Strategies for the 21st Century

  • 0
  • 03 Nov

Post-approval research studies are vastly different from pre-market studies designed for the registration of a new drug or device. In the white paper "One Size Doesn’t Fit All": Applying an Innovative Mindset to Post-Approval Research, I outline these differences and illustrate why companies ought to leverage strategies, processes, standard operating procedures (SOPs), and technologies that are specifically designed for and more relevant to post-approval research.

Read More

Post-Approval Research: Do You Have What It Takes?

  • 0
  • 08 Sep

Investments in post-approval research are rising steadily year on year. Chances are, post-approval research represents a substantial part of your annual budget. But how much of that money is being wasted by conducting post-approval studies in an inappropriate and inefficient manner?

Read More

Explosive Growth in Post-Approval Research Drives Increased Cost and Complexity

  • 0
  • 04 Aug

In the 1970s, post-approval studies were rarely performed. The 1980s saw a slight rise when the FDA began to require post-approval research as a condition for the approval of certain drugs. Fast forward to 2014, when a full 13.7% of total R&D costs was spent on conducting post-approval studies. What fueled this explosive growth in post-approval research in such a relatively short period of time? And – critically – what are the ramifications of that growth?

Read More

Necessity and Associated Benefits of Having Post-Approval Specific Technology

  • 0
  • 26 Jan

Over the last decade, across the globe, the regulatory landscape has changed considerably, with greater focus and awareness on pharmaceutical products post-approval. Legislation, coupled with public concerns about the safety of marketed drugs and the need to evaluate safety and effectiveness of the marketed products in a real-world setting is forcing many companies to embark on post-approval research.

Read More

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @eClinical_Jen: FREE on-demand webinars from @bioclinica on EDC, Imaging, RBM, and Clinical Trial Management. Tell them I sent you! http…
bioclinica (14 hours ago)
Excited to host NJ Lt. Gov. Kim Guadagno, clients, partners 9/28 in Princeton! In the area? Join us ! RSVP… https://t.co/PrfyxvasGb
bioclinica (Yesterday)
Be sure to follow #ThankAScientist all week to thank researchers for the work they do! https://t.co/Sfi9mmHbSk… https://t.co/y9ZhBXsIzu
bioclinica (2 days ago)
Cardiovascular imaging use is growing in non-cardiovascular areas #ClinicalTrials. See where in Tim Crowe's blog… https://t.co/dYjPBC0Wtn
bioclinica (2 days ago)
RT @Xtalks: Cardiovascular Safety in #Biopharmaceutical Product Development - From QT Prolongation and Beyond @bioclinica https://t.co/mCk1…
bioclinica (2 days ago)
RT @Xtalks: How Innovations in Data Visualization Are Accelerating Data Cleaning and Improving Quality @bioclinica https://t.co/vfLU8pS9Rd
bioclinica (2 days ago)

Latest Blogs: